New results from the international Phase 3 RASolute 302 clinical trial (NCT06625320) have generated interest in pancreatic cancer research after the investigational drug daraxonrasib demonstrated improved survival outcomes in patients with previously treated metastatic pancreatic cancer, an area where treatment options remain limited.

The study evaluated daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma whose cancer had progressed after prior chemotherapy. Patients who received daraxonrasib survived longer on average than those who received standard chemotherapy treatment. Reported median overall survival was 13.2 months with daraxonrasib, compared with 6.7 months with chemotherapy.

The trial also reported improvements in progression-free survival, which refers to the length of time before the cancer worsens. Overall, side effects were considered manageable. The most commonly reported side effects included rash, nausea, and diarrhoea.

RASolute 302 is one of the first late-stage pancreatic cancer trials to report encouraging results with a broader RAS-targeted therapy.

Why is this study important?

More than 90% of pancreatic cancers contain changes in the KRAS or RAS pathway, which helps drive cancer growth. Despite this, treatments that successfully target these pathways have historically been difficult to develop in pancreatic cancer.

Daraxonrasib is an oral therapy designed to block a broad range of RAS mutations that help pancreatic cancer cells grow. Earlier drugs targeted only individual mutations, which limited the number of patients who may benefit. Because daraxonrasib targets a wider range of RAS mutations, researchers hope it may help a larger proportion of people with pancreatic cancer.

The results from RASolute 302 contribute to growing international efforts to develop more effective treatments for pancreatic cancer, particularly in advanced disease where treatment options remain limited.

RASolute 303 opening at Epworth

The Jreissati Pancreatic Centre at Epworth is preparing to open the RASolute 303 clinical trial (NCT07491445) in July 2026. The study will recruit participants at Epworth Richmond, Freemasons, and Eastern.

RASolute 303 is an international first-line clinical trial for patients with metastatic PDAC. The study is evaluating daraxonrasib with or without chemotherapy, compared with standard chemotherapy alone, in patients who have not previously received treatment for metastatic disease.

“Pancreatic cancer remains one of the most challenging cancers to treat, and advances in this area have historically been limited,” said A/Professor Sumitra Ananda, who is leading the study at Epworth as Principal Investigator. “The results from RASolute 302 are encouraging because they suggest that targeting the RAS pathway may offer a new treatment approach for some patients with advanced pancreatic cancer. We are pleased to be opening the RASolute 303 study at Epworth and contributing to international research efforts focused on improving outcomes for patients.”

For more information, please contact our research trials team at [email protected]

Further information